| CRSP |
CRISPR Therapeutics AG |
72%
|
Reciprocal relationship from CRSP graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from CRSP g… |
| CRSP |
CRISPR Therapeutics AG |
72%
|
f period $ $ $ Supplemental disclosure of cash flow information: Cash paid for income taxes $ $ $ Cash paid for interest $ $ $ Net payments due to CRISPR Therapeutics AG related to finite-lived intan… |
| EDIT |
Editas Medicine, Inc. |
72%
|
Reciprocal relationship from EDIT graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from EDIT g… |
| EDIT |
Editas Medicine, Inc. |
72%
|
SPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40 % share of these research and development activities, subject to certain adjustments… |
| MCK |
McKesson Corporation |
72%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from VRTX graph: rty and equipment, net by location are presented below. F-47 VERTEX PHARMACEUTICALS INCORPORATED Notes to Consolidated… |
| MCK |
McKesson Corporation |
72%
|
rty and equipment, net by location are presented below. F-47 VERTEX PHARMACEUTICALS INCORPORATED Notes to Consolidated Financial Statements (Continued) Revenues by Product Product revenues, net consi… |
| MRNA |
Moderna, Inc. |
72%
|
Reciprocal relationship from MRNA graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA g… |
| NTLA |
Intellia Therapeutics, Inc. |
72%
|
Reciprocal relationship from NTLA graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from VRTX graph: portunities and challenges; • the p… |
| NTLA |
Intellia Therapeutics, Inc. |
72%
|
portunities and challenges; • the potential loss of key employees of an acquired company; • entry into markets in which we have no or limited direct prior experience or where competitors in such mark… |
| RPRX |
Royalty Pharma plc |
72%
|
l expansions for our current medicines. We expect to continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEVY, JOURNAVX, and, ultimately, our pipelin… |
| RPRX |
Royalty Pharma plc |
72%
|
Reciprocal relationship from RPRX graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from VRTX graph: l expansions for our current medici… |
| TRDA |
Entrada Therapeutics, Inc. |
72%
|
Research and development expenses .” We also share with CRISPR % of the net commercial profits or losses incurred with respect to CASGEVY, subject to certain adjustments, which is recorded to “ Cost … |
| TRDA |
Entrada Therapeutics, Inc. |
72%
|
Reciprocal relationship from TRDA graph: Reciprocal relationship from VRTX graph: Research and development expenses .” We also share with CRISPR % of the net commercial profits or losses incurred wit… |
| ZLAB |
Zai Lab Limited |
72%
|
f period $ $ $ Supplemental disclosure of cash flow information: Cash paid for income taxes $ $ $ Cash paid for interest $ $ $ Net payments due to CRISPR Therapeutics AG related to finite-lived intan… |
| ZLAB |
Zai Lab Limited |
72%
|
Reciprocal relationship from ZLAB graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from VRTX graph: f period $ $ $ Supplemental disclos… |
| ACCREDO-HEALTH-GROUP-INC |
ACCREDO-HEALTH-GROUP-INC |
62%
|
rty and equipment, net by location are presented below. F-47 VERTEX PHARMACEUTICALS INCORPORATED Notes to Consolidated Financial Statements (Continued) Revenues by Product Product revenues, net consi… |
| ALPINE-IMMUNE-SCIENCES-INC |
ALPINE-IMMUNE-SCIENCES-INC |
62%
|
n of Alpine Immune Sciences, Inc. (“Alpine”) as discussed below. Asset Acquisitions Alpine Immune Sciences, Inc. - povetacicept On May 20, 2024, we acquired all of the issued and outstanding shares o… |
| CVC-GROUP |
CVC-GROUP |
62%
|
portunities and challenges; • the potential loss of key employees of an acquired company; • entry into markets in which we have no or limited direct prior experience or where competitors in such mark… |
| CVC-GROUP-THE-CVC-GROUP |
CVC-GROUP-THE-CVC-GROUP |
62%
|
portunities and challenges; • the potential loss of key employees of an acquired company; • entry into markets in which we have no or limited direct prior experience or where competitors in such mark… |
| CYSTIC-FIBROSIS-FOUNDATION-THERAPEUTICS-INC |
CYSTIC-FIBROSIS-FOUNDATION-THERAPEUTICS-INC |
62%
|
SPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40 % share of these research and development activities, subject to certain adjustments… |
| EXONICS-THERAPEUTICS-INC |
EXONICS-THERAPEUTICS-INC |
62%
|
SPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40 % share of these research and development activities, subject to certain adjustments… |
| ONO-PHARMACEUTICALS-CO-LTD |
ONO-PHARMACEUTICALS-CO-LTD |
62%
|
l expansions for our current medicines. We expect to continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEVY, JOURNAVX, and, ultimately, our pipelin… |
| SEMMA-THERAPEUTICS-INC |
SEMMA-THERAPEUTICS-INC |
62%
|
ate and research and development strategies and complement and advance our ongoing research and development efforts. We have acquired multiple biotechnology companies over the last several years and … |
